APOL1-Mediated Kidney Disease

APOL1-mediated kidney disease is a genetic kidney condition driven by two specific variants in the APOL1 gene, called G1 and G2, that arose in West Africa and are carried at high frequency by people of recent West African ancestry. Roughly 13% of African Americans inherit two high-risk copies (one from each parent), the configuration that drives risk. Carrying two copies does not guarantee kidney disease, but it raises the lifetime risk of chronic kidney disease (CKD) 5- to 10-fold, accelerates progression once disease starts, and accounts for a meaningful share of the long-documented Black-white gap in kidney failure rates. The condition typically presents as focal segmental glomerulosclerosis (FSGS), hypertension-attributed nephropathy, HIV-associated nephropathy, or rapidly progressive non-diabetic CKD. A targeted oral therapy, inaxaplin, is in late-stage trials.

• Foamy or bubbly urine (a sign of protein in the urine, often the first clue)
• Swelling in the ankles, feet, hands, or around the eyes
• Fatigue that does not improve with rest
• High blood pressure that is hard to control, especially before age 50
• Reduced urine output, dark urine, or urine that looks tea-colored
• Itchy skin, muscle cramps, or trouble sleeping in later stages
• Shortness of breath from fluid buildup
• Nausea, loss of appetite, or a metallic taste in the mouth as kidney function drops

Early disease is usually silent. Many people have no symptoms until proteinuria is found on a routine urine test or kidney function has already dropped significantly.

There is no consensus that every Black person should be screened for APOL1 variants, and the medical community is openly working through that question. The current state in 2026:

Who is offered testing. A 2024 clinical review in JAMA by Hopper and Olabisi summarized the field consensus that population-wide APOL1 screening is not yet recommended, but testing should be offered to people with recent West African ancestry who have non-diabetic CKD, unexplained proteinuria, FSGS on biopsy, or a family history of kidney disease. The American Society of Transplantation's 2025 living-donor guidance recommends discussing APOL1 testing with any prospective living kidney donor who self-reports recent African ancestry, well before the donor evaluation closes, and supports shared decision-making rather than automatic exclusion if two high-risk variants are found.

How testing is done. A simple blood or saliva test sequences the APOL1 gene for the G1 and G2 variants. Results return as one of three genotypes: 0, 1, or 2 high-risk alleles. Only two high-risk alleles confer the strong disease risk. One copy is essentially neutral for kidney disease.

The honest controversies. A positive result (two high-risk variants) means elevated lifetime risk, not a guarantee. Estimated lifetime risk of kidney disease in someone with two copies is around 15%, which means most carriers never develop the disease. That uncertainty creates real problems: the Genetic Information Nondiscrimination Act (GINA) bars health-insurance and employment discrimination based on genetic results, but it does not cover life insurance, disability insurance, or long-term care insurance. People considering testing should know this before they consent. Pre- and post-test genetic counseling is recommended by every major group that has weighed in. The race-based eGFR equation was retired in 2021 (NKF-ASN Task Force, Delgado et al., JASN 2021) in part because APOL1 made clear that race was being used as a poor proxy for a genetic risk only some Black patients carry. The replacement CKD-EPI 2021 equation removes race; many labs also report cystatin C-based eGFR for confirmation.

There is no FDA-approved therapy specifically for APOL1-mediated kidney disease as of May 2026. Standard care is the same backbone used for other proteinuric kidney disease: tight blood pressure control (target generally below 130/80), an ACE inhibitor or ARB to reduce proteinuria, an SGLT2 inhibitor (dapagliflozin or empagliflozin) which now has strong evidence in non-diabetic proteinuric CKD, careful management of lipids and cardiovascular risk, and avoidance of nephrotoxic drugs including chronic high-dose NSAIDs.

Inaxaplin (VX-147) is the first APOL1-targeted therapy. Developed by Vertex, it is a small molecule that blocks the toxic activity of the APOL1 protein inside kidney cells. The Phase 2a open-label study (Egbuna et al., NEJM 2023; PMID 36920755) enrolled 16 participants with two APOL1 variants and biopsy-proven FSGS. After 13 weeks, the urine protein-to-creatinine ratio dropped 47.6%, with mild-to-moderate side effects and no discontinuations. The FDA granted Breakthrough Therapy designation.

AMPLITUDE is the ongoing Phase 2/3 adaptive trial (NCT05312879) testing inaxaplin 45 mg once daily versus placebo on top of standard of care in adults and adolescents with APOL1-mediated kidney disease. Vertex announced completion of the interim-analysis cohort enrollment in late 2025; a positive interim readout would support accelerated FDA approval. Anyone who fits the diagnostic criteria should ask their nephrologist about enrollment.

I could not verify the existence of trials named "AVANTI" or "ONELINER" in APOL1-mediated kidney disease, so this entry covers AMPLITUDE and the Egbuna Phase 2a study, which are the confirmed inaxaplin trials in the published record.

For people who progress to kidney failure, dialysis and transplant remain the mainstays. APOL1 testing of living donors is now part of standard transplant evaluation when the donor reports West African ancestry, because two high-risk variants in the donated kidney predict faster post-transplant function loss.